I forgot mentione Rilutek! REGN and Medtronic will overcame carent problems. I first bougth at 18 in midle Sep, and didn't sold at 24. After 3-10Q report, many investor start to wory about prospects of BDNF trials. Low average dayly volumen indicate patience, and after PG anauncment (specialy that equety payment by PG will be in first half of 1997), REGN actualy said that final result will be completed by Feb-March. I think that this is a reason for drop in price. I still bolive in positive results for BDNF(bought more Friday at 15 7/8 after several block bayers), missed today, but I hope I will have a chance tomorow. As you wrote, definetly research potential(15 patents, meny in years to come), proven manufacturing capability( Sumitomo and Merck), and carent coloboration partners show that REGN will grow sarply in 1997. Sadenly drop is chance for new enters, and for as to reinforce positions!
Good luck, and best wish in 1997.
Miljenko
|
